文献速递放疗物理与技术

放射肿瘤学 Medicare 报销随时间下降:按计费代码分析

Decreases in Radiation Oncology Medicare Reimbursement Over Time: Analysis by Billing Code.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-05-22

该研究比较了2010、2015和2019年放射肿瘤学特定HCPCS代码的Medicare报销总额,并按通胀和利用率调整。按2019年利用率调整后降幅为27%。调强放疗(IMRT)报销下降是主要驱动因素。

要点

  • IMRT治疗和计划报销占比从2010年36%降至2019年31%,是报销下降的主要驱动因素。

核心结论

  • Medicare报销从2010年到2019年大幅下降,IMRT治疗报销下降是主要驱动因素;政策制定者在考虑进一步削减时应考虑这些趋势及其对医疗质量和可及性的影响。

研究设计与样本

  • 使用美国医疗保险和医疗补助服务中心(CMS)医师/供应商程序汇总数据库,获取2010、2015和2019年放射肿瘤学HCPCS代码的Medicare报销数据。
  • 对每个代码,将总允许费用除以提交的索赔数量,计算2010、2015和2019年每次索赔的平均报销。
  • 将2019年每个代码的计费频率乘以2010和2015年经通胀调整的平均报销,以确定使用2019年美元和利用率时2010和2015年的报销额(调整后报销)。
  • 将结果与实际2019年报销比较,计算预计差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation oncology (RO) has seen declines in Medicare reimbursement (MCR). However, there are no recent studies analyzing the contributions of specific billing codes to overall RO reimbursement. We compared total MCR for specific Healthcare Common Procedure Coding System (HCPCS) codes in 2019 with MCR for those codes in 2010 and 2015, corrected for inflation, to see how the same basket of RO services in 2019 would have been reimbursed in 2010 and 2015 (adjusted MCR). METHODS AND MATERIALS: The Centers for Medicare & Medicaid Services Physician/Supplier Procedure Summary database was used to obtain MCR data for RO HCPCS codes in 2010, 2015, and 2019. For each code, the total allowed charge was divided by the number of submitted claims to calculate the average MCR per claim in 2010, 2015, and 2019. The 2019 billing frequency for each code was then multiplied by the inflation-adjusted average MCR for those codes in 2010 and 2015 to determine what the MCR would have been in 2010 and 2015 using 2019 dollars and utilization rates. Results were compared with actual 2019 MCR to calculate the projected difference. RESULTS: Total inflation-adjusted RO MCR was $2281 million (M), $1991 M, and $1848 M in 2010, 2015, and 2019 respectively. This represents a cut of $433 M (19%) and $143 M (7%) from 2010 and 2015, respectively, to 2019. After utilization adjustment, total reimbursement was $2534 M, $2034 M, and $1848 M for 2010, 2015, and 2019, respectively, representing a cut of $686 M (27%) and $186 M (9%) from 2010 and 2015, respectively, to 2019. Intensity modulated radiation therapy (IMRT) treatment delivery and planning accounted for $917 M (36%), $670 M (33%), and $573 M (31%) of the adjusted MCR in 2010, 2015, and 2019, respectively. CONCLUSIONS: Medicare reimbursement decreased substantially from 2010 to 2019. A decline in IMRT treatment reimbursement was the primary driver of MCR decline. When considering further cuts, policymakers should consider these trends and their consequences for health care quality and access.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hogan J, Roy A, Karraker P, et al. Decreases in Radiation Oncology Medicare Reimbursement Over Time: Analysis by Billing Code. Int J Radiat Oncol Biol Phys. 2022. PMID: 35613687. doi:10.1016/j.ijrobp.2022.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。